Should You Buy Shares of Intuitive Surgical in December?

Intuitive Surgical (ISRG) reported strong Q3 2025 results—10,763 da Vinci systems installed (+13% YoY) and robot procedures up 20%—prompting a >20% rally after the stock recovered from an October 52-week low. The installed base drives an annuity-like revenue mix (services and instruments ≈75% of sales) and the company is incorporating AI, supporting durable growth potential. However, shares now trade at elevated multiples (P/S 21 vs five-year avg 18.5; P/E 73.5 vs five-year avg 72; P/B 11.6 vs five-year avg 9.3 and well above the S&P P/E ~28.5), suggesting the high-quality business may be fully priced and is primarily appropriate for aggressive growth investors.

Analysis

Intuitive Surgical reported robust third-quarter 2025 operational results with 10,763 da Vinci systems installed globally, a 13% year‑over‑year increase in the installed base and a 20% rise in procedures, underscoring strong demand for robotic-assisted surgery and reinforcing the company's recurring-revenue model where services and instruments comprise roughly 75% of revenue. The company is integrating AI into its products and sits in some AI-focused ETFs, highlighting longer-term optionality around software and automation even as fully autonomous surgery remains a longer-term prospect.

Market reaction was swift: shares rebounded from an October 52-week low (about 30% below the 52-week high) and rallied more than 20% in roughly a month after the earnings print. That recovery pushed valuation metrics above historical averages—P/S 21 versus a five‑year average of 18.5, P/E 73.5 versus five‑year 72, and P/B 11.6 versus five‑year 9.3—well above the S&P 500's P/E (~28.5), producing a mixed, cautious market sentiment (sentiment_score -0.05; market_impact_score 0.25).

The fundamental picture is high quality with durable annuity-like revenue, but current prices appear to price in continued robust growth and AI upside; this narrows the margin for error and makes the stock more appropriate for aggressive growth investors or those willing to manage valuation risk. Key near-term indicators to watch are sequential install growth, procedure volume trends, AI commercialization milestones and guidance that could validate further multiple expansion or signal a pullback risk.

Key Decisions for Investors

• Avoid initiating a full-sized position at current levels given elevated P/S, P/E and P/B relative to history and the S&P, consider only a smaller, tactical allocation if conviction is strong
• Aggressive growth investors who prioritize exposure to surgical robotics and AI can consider staged buys or dollar-cost averaging to manage valuation risk while monitoring execution against procedure and install growth
• Monitor catalysts that would justify a higher valuation—sustained procedure growth above the reported 20% YoY, clear revenue contribution from AI offerings, or upward guidance—and reassess positions if these do not materialize
• If maintaining long exposure, implement risk controls such as position size limits or hedges and watch quarterly installs, procedure growth, and guidance for early signs of deceleration